Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis
| Autor: | Wayne Weng, Manuel R. Morman, Joel S. Shavin, David M. Pariser, Cesar Samsom, Jonathan S. Weiss, Renie Bressinck, Robert J. Pariser, H.Irving Katz, Roger C. Cornell, Jane S. Lindholm |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Erythema Adolescent medicine.drug_class Administration Topical Anti-Inflammatory Agents Betamethasone dipropionate Betamethasone law.invention Randomized controlled trial Double-Blind Method law Psoriasis medicine Humans Pharmacology (medical) Adverse effect Glucocorticoids Aged Pharmacology Aged 80 and over Clobetasol business.industry Middle Aged medicine.disease Dermatology Scalp Dermatoses Lotion Corticosteroid Female Clobetasol propionate medicine.symptom business medicine.drug |
| Zdroj: | Clinical therapeutics. 17(3) |
| ISSN: | 0149-2918 |
| Popis: | This 2-week, randomized, multicenter, investigator-blinded, parallel-group study was conducted to compare the efficacy and safety of augmented betamethasone dipropionate 0.05% lotion and clobetasol propionate 0.05% solution in the treatment of moderate-to-severe scalp psoriasis among 197 (193 assessable) healthy adult patients with at least 20% scalp-surface involvement. The patients received one of two treatments applied twice a day for 2 weeks. Signs and symptoms were evaluated at baseline, after 3 days (day 4), and after weeks 1 (day 8) and 2 (day 15) of treatment. As early as 3 days after treatment, scaling and induration were improved significantly faster by betamethasone dipropionate than by clobetasol propionate. Both treatments also reduced erythema and pruritus. Patients receiving betamethasone dipropionate had a significantly greater mean percent improvement in total sign/symptom scores (P < or = 0.015) at all visits and better mean global clinical response scores at the early visits (days 4 and 8) (P < or = 0.017). At the end of the study, only mild disease was present in both groups. Adverse events were reported by 34.0% and 36.4% of patients receiving betamethasone dipropionate and clobetasol propionate, respectively. All events were transient, most were mild and local, and no discontinuations resulted. The effects of treatment on the hypothalamic-pituitary-adrenal axis were not measured. In conclusion, augmented betamethasone dipropionate lotion and clobetasol propionate solution were equally effective, but betamethasone dipropionate lotion provided a faster onset of relief for scaling and induration, which may enhance patient compliance and patient satisfaction with treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect